Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 72
- Registration Number
- NCT06713590
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5621
- Registration Number
- NCT06627335
- Locations
- 🇺🇸
Syneos Health (remote site), Morrisville, North Carolina, United States
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 572
- Registration Number
- NCT06615050
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 240
- Registration Number
- NCT06585774
- Locations
- 🇯🇵
National Hospital Organization Kumamoto Medical Center, Kumamoto Kumamoto, Japan
🇺🇸Prisma Health Upstate, Greenville, South Carolina, United States
A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 168
- Registration Number
- NCT06555081
- Locations
- 🇺🇸
Celerion Clinical Research Unit, Tempe, Arizona, United States
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 180
- Registration Number
- NCT06548360
- Locations
- 🇺🇸
3A Research Llc West Location, El Paso, Texas, United States
🇨🇦Childrens Hospital of Eastern Ontario, Ottawa, Ontario, Canada
🇺🇸Affiliated Dermatology, Scottsdale, Arizona, United States
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT06516965
- Locations
- 🇺🇸
Yardley Dermatology Associates, Yardley, Pennsylvania, United States
🇺🇸Fivenson Dermatology, Ann Arbor, Michigan, United States
🇺🇸Medical Dermatology Specialists Phoenix, Phoenix, Arizona, United States
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT06516952
- Locations
- 🇺🇸
Cahaba Dermatology, Birmingham, Alabama, United States
🇺🇸Banner - University Medicine Multispecialty Services Clinic, Tucson, Arizona, United States
🇺🇸Premier Dermatology Clinical Trials Institute At Northwest Arkansas, Fayetteville, Arkansas, United States
A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT06505265
- Locations
- 🇺🇸
Celerion, Inc, Lincoln, Nebraska, United States
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT06465433
- Locations
- 🇹🇷
Gazi University Hospital Gazi University Faculty of Medicine, Ankara, Turkey
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇮🇹Hospital S.M. Terni University of Perugia, Terni, Italy